Shire PLC Vice President Hartmann Wellhoefer, Head of Genetic Diseases, Medical Affairs, recently spoke with Scrip about the company's research and development pipeline in lysosomal disorders and hereditary angioedema (HAE), noting that more patients with those conditions will have access to Shire's medicines after its purchase of Baxalta Inc.
"The biggest advantage in genetic diseases from Baxalta was expanding our presence into more countries," Wellhoefer said in a Feb....





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

